Next-Generation Anastomosis System for Minimally Invasive Surgery
Legal Citation
Summary of the Inventive Concept
A next-generation anastomosis system integrating nanorobotics, micro-suturing, and bio-absorbable materials for minimally invasive, high-precision surgical procedures.
Background and Problem Solved
The original patent disclosed methods and apparatuses for partial eversion anastomosis juncture formation and suturing. However, these methods are limited by their invasive nature, reliance on manual suturing, and potential for complications. The new inventive concept addresses these limitations by introducing a minimally invasive, automated, and adaptive anastomosis system.
Detailed Description of the Inventive Concept
The next-generation anastomosis system comprises a nanorobotics-based eversion mechanism, a micro-suturing module, and a bio-absorbable, shape-memory alloy stent. The nanorobotics-based eversion mechanism inverts a portion of an edge around an opening of a receiving passage, while the micro-suturing module joins the receiving passage to a donor passage. The bio-absorbable stent maintains the patency of the receiving passage during the anastomosis procedure and is subsequently absorbed after the procedure is complete. The system is controlled by a computer-aided design (CAD) system that predicts optimal suturing patterns and passage geometries based on patient-specific data and provides real-time feedback to the surgeon.
Novelty and Inventive Step
The new inventive concept's integration of nanorobotics, micro-suturing, and bio-absorbable materials represents a paradigm shift in anastomosis procedures, offering a minimally invasive, high-precision, and adaptive solution that overcomes the limitations of the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different nanorobotics architectures, micro-suturing materials, or bio-absorbable alloys. Variations could also include the integration of additional features, such as real-time imaging or haptic feedback, to further enhance the system's performance and usability.
Potential Commercial Applications and Market
The next-generation anastomosis system has significant commercial potential in the medical device industry, particularly in the areas of cardiovascular, gastrointestinal, and neurosurgery. The system's minimally invasive nature, high precision, and adaptability make it an attractive solution for surgeons and hospitals seeking to improve patient outcomes and reduce healthcare costs.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61B17/1152 |
| A | A61 | A61B17/0469 |
| A | A61 | A61B17/11 |
| A | A61 | A61B90/361 |
| A | A61 | A61B90/37 |
| A | A61 | A61B2017/00566 |
| A | A61 | A61B2017/1107 |
| A | A61 | A61B2017/1121 |
| A | A61 | A61B2017/1125 |
| A | A61 | A61B2017/1132 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Surgical Intervention Technologies, specifically minimally invasive surgical techniques for passage reconnection and anastomosis, requiring advanced knowledge of medical device engineering, microsurgical techniques, and biomedical materials science
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or surgical technology specialist with advanced degrees, expertise in medical device design, understanding of microsurgical techniques, familiarity with robotic surgical systems, and knowledge of biomaterials and surgical intervention strategies
Obviousness Rationale
A PHOSITA would recognize that the PTD's nanorobotics-based eversion and micro-suturing approach represents a predictable technological progression from the source patent's fundamental anastomosis method, utilizing known engineering principles of miniaturization, automation, and patient-specific customization to enhance surgical precision and reduce invasiveness.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,193 |
|---|---|
| Title | Partial eversion anastomosis juncture formation and suturing |
| Assignee(s) | Gyrus ACMI, Inc. |